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Background. Many studies have reported an association between tea drinking and Parkinson’s disease (PD). Our purpose is
to summarize the available information and evaluate the risk of PD associated with tea drinking. Methods. We searched all
publications in English language on the association of tea drinking and PD risk published up to December 2010. The pooled
analysis was performed with Review Manager 5.0. Results. In total, eight articles including 1418 cases and 4250 controls were
included in the meta-analysis. The pooled odds ratio (95% CI) was 0.85 (0.74–0.98), which suggests the protective eﬀect of tea
drinking in PD risks. Moreover, the summary OR (OR: 0.83, 95% CI = 0.69–0.99) for drinkers of ≤1 cup of tea per day versus
nonconsumers and that (OR: 0.96, 95% CI = 0.73–1.27) for drinkers of >1 cups of tea per day versus nonconsumers showed
that there was not an apparent dose-response relationship. No indication for publication bias was found. Conclusions. This meta-
analysis showed that tea drinking can lower the risk of PD, while no apparent dose-response relationship was found. Further eﬀort
is needed to fully understand the mechanism underlying the beneﬁcial eﬀect of tea consumption in lowering PD risk.
1.Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder, and, with the accelerated aging of human society,
the prevalence of PD is expected to rise steadily in future
[1, 2]. Despite the pathogenesis of PD is not fully elucidated,
many epidemiological factors, such as coﬀee drinking and
smoking, have been demonstrated to lower the risk of PD
[3–5]. Tea is one of the most popular beverages worldwide,
and the eﬀects of tea consumption on PD risk have at-
tracted much attention in recent years [6–17], as the tea
components, such as ﬂavonoids, caﬀeine, and theanine, have
been proven to be neuroprotective in animal models of PD.
Many studies have found that tea drinking can lower the
risk of PD [6–10, 12–15], while this beneﬁcial eﬀect of tea
is not observed in other reports [11, 16]. The purpose of
the present study was to perform a meta-analysis to provide
a comprehensive conclusion on the association between tea
drinking and PD risk, which has important implications for
the prevention and treatment of this disease.
2. Methods
2.1. Information Retrieval. We identiﬁed procurable pub-
lished studies in English through a computerized MEDLINE
search from 1966 to December 2010 and also the rela-
tional document links. We used the following medical
subject headings and free text words to search the PubMed
database: (TEA) AND (PARKINSON OR PD) AND (CASE-
CONTROL OR CASE-REFERENT OR RETROSPECTIVE
OR COHORT OR FOLLOW-UP OR INCIDENCE OR
PROSPECTIVE OR EPIDEMIOLOG). We also examined
conference proceedings; the references in the articles re-
trieved through the computerized search.
2.2. Selection Criteria. The identiﬁed studies must meet the
following criteria: (i) the original data includes the number
of PD cases studied and the odds ratio (OR) or relative risk
(RR), (ii) its corresponding 95% conﬁdence interval (CI) is
for highest versus non-/lowest level of tea intake, and (iii)
these studies must deﬁne the outcome of interest as incident
PD based on clearly stated diagnostic criteria or identiﬁed
through diagnostic codes with additional conﬁrmation. In
total, eight published articles were included in the meta-
analysis [8–15]. The details of search strategy and study
selection processes were shown in Figure 1.
2.3. Data Extraction and Meta-Analysis. We extracted infor-


























Figure 1: Selection of studies for inclusion in the present meta-analysis.
country of publication, the number of cases and controls,
the adjusted RRs or ORs, and 95% CI. We examined possible
heterogeneity in the identiﬁed result. If the P value >0.10, it
means that the study does not have statistical signiﬁcance.
We used the ﬁxed eﬀect model to calculate the summary
OR and its 95% CI across homogeneous studies and used
the random eﬀect model to calculate the summary OR and
its 95% CI across heterogeneous studies. Egger’s weighted
regression method was employed to evaluate P value for
publication bias. Finally, stratiﬁed analyses were conducted
to examine the diﬀerences by cups of drinking. Statistical
computation was performed using the Review Manager 5.0
statistical software.
3. Results
3.1. Tea Drinking and PD Risks. The eight case-control
studies (including 1418 cases and 4250 controls) which met
the eligibility criteria were conducted in 5 countries between
1966 and 2010. Table 1 with the extracted information
present the relative risk for each of studies along with
their summary OR derived from the meta-analysis. Figure 2
presents the forest plot of comparison of tea drinkers versus
non-consumers. There was statistically heterogeneity among
the eight results (P = 0.04). The analyses compared exposed
with unexposed for tea drinking, and the overall summary
OR based on all studies indicated that tea drinking can
protect PD (summary OR = 0.85, 95% CI = 0.85–0.98) with
eight cases.
3.2. The Dose Eﬀect Relationship of Tea Drinking and PD
Risks. Among the eight studies that included in our present
analysis, three reported the results for drinkers of ≤1a n d>1
cup of tea per day versus non-consumers. [14, 16, 18]. The
information according to the number of cups of tea drinking
daily was included in Table 2. It can be seen that, for drinkers
of ≤1cupofteaperdayversusnon-consumers,thesummary
OR (OR: 0.83, 95% CI = 0.69–0.99) showed a protective
eﬀect against PD (Figure 3). For drinkers of >1c u po ft e a
per day versus non-consumers, the summary OR (OR: 0.96,
95% CI = 0.73–1.27) also showed a protective eﬀect (Figure
4). According to the present results, we concluded that there
was not an apparent dose-response relationship.
3.3. Publication Bias. Figure 5 shows the funnel plot of tea
drinking and the risk of PD, in which, the logOR from each
study is plotted on the horizontal axis, and its standard error
is plotted on the vertical axis. Inspection of the Begg funnel
plot did not ﬁnd the presence of publication bias because
the logORs plotted against their standard errors yielded a
symmetric distribution.The Scientiﬁc World Journal 3
Table 1: Tea drinking and PD risk.
Author Year of publication Country Cases Controls Relative risk 95% CI
NnNn
Haack et al. [8] 1981 USA 237 223 474 456 0.63 [0.31, 1.29]
Ho et al. [9] 1989 China 34 21 105 70 0.81 [0.36, 1.80]
Fall et al. [10] 1999 Sweden 113 64 263 174 0.67 [0.43, 1.05]
Preux et al. [11] 2000 France 140 40 280 54 1.67 [1.04, 2.68]
Paganini-Hill [12] 2001 USA 395 182 2320 1126 0.91 [0.73, 1.12]
Morano et al. [13] 1994 Spain 74 6 148 6 2.09 [0.65, 6.71]
Chan et al. [14] 1998 China 215 113 313 196 0.66 [0.46, 0.94]
Checkoway et al. [15] 2002 USA 210 72 347 145 0.73 [0.51, 1.04]
Total 1418 4250 0.85 [0.74, 0.98]
Test for heterogeneity among all studies: Q = 15.03 based on 7 degrees of freedom P = 0.04. Summary OR was based on ﬁxed eﬀect models. N :n u m b e ro f
cases/controls, n : number of tea drinkers in cases/controls.
Study or subgroup
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
Chan et al. [14]
Checkoway et al. [15]
Fall et al. [10]
Haack et al. [8]
Ho et al. [9]
Morano et al. [13]
Paganini-Hill [12]









0.85 [0.74, 0.98] Total (95% CI)
Total events
Heterogeneity: χ2 = 15.03, df = 7( P = 0.04), I2 = 53%
Test for overall eﬀect: Z = 2.3( P = 0.02) 0.02 0.1 11 0 50
Favours experimental Favours control
Figure 2: Pooled estimate of OR and 95% CI of PD riskfor tea drinking. Bluediamonds indicate adjusted OR in each study. Open diamonds
are pooled OR. Horizontal line represents 95% CI. Studies are ordered by alphabetical order of last name of ﬁrst author.
4. Discussion
As we know, PD is a common neurodegenerative disorder
in middle- and old-aged crowd. The etiology of PD has
long been thought to involve many factors, and there
were ﬁve major hypotheses regarding the pathogenesis of
PD, such as the theory of genetic factors, the theory of
environmental factors, immunity doctrine, apoptosis theory,
and the oxidative stress theory [18–22]. In oxidative stress
theory, oxidative stress contributes to the cascade leading
to dopamine cell degeneration in PD. Oxidative stress can
impair altered ubiquitination and degradation of proteins
directly, which have been implicated as key to dopaminergic
cell death in PD, and products of oxidative damage (e.g.,4 -
hydroxynonenal) can damage the 26S proteasome [23].
Tea is one of the most ancient and popular beverages
consumedaroundtheworld.Therearemanyimportantsub-
stances in tea leaves, such as polyphenols, methylxanthine,
caﬀeine, diﬀerent lipids, amino acids, mineral substances,
and volatile compounds. The demonstrated health beneﬁts
of tea include weight loss, preventing heart disease and
cancer, and so forth [24]. For example, epigallocatechin
gallate (EGCG), one of the most important antioxidant
ingredients of green tea, is responsible for green tea’s weight
loss eﬀect by increasing metabolism and the body’s ability to
burn fat [25]. Polyphenols in tea have been proven to inhibit
tumor cell proliferation and induce apoptosis [26, 27].
Moreover, in in vitro study and experimental animal model,
it has been identiﬁed that tea drinking can obviously reduce
the formation of molecular products of various small lipid
peroxidationandinduceantioxidativeenzymeactivities[28].
In recent years, there were more and more studies
devoted to exploring the eﬀects of tea consumption on PD
risk. Many studies reported that tea drinking can lower the
risk of PD [6–10, 12–15], while this protective eﬀect of tea
is not demonstrated by other groups [11, 16]. With the aim
to evaluate the association between tea drinking and PD risk,
a meta-analysis was conducted based on published studies.
The estimated summary OR is 0.85, which donates that tea4 The Scientiﬁc World Journal
Table 2: The dose eﬀect relationship of tea drinking and PD risk.
Author Year of publication Country Cases Controls Relative risk 95% CI
NnNn
Drinkers of ≤1 cup per day of tea versus non-consumers studies
Fall et al. [10] 1999 Sweden 113 57 263 143 0.85 [0.55, 1.33]
Paganini-Hill [12] 2001 USA 395 132 2320 892 0.80 [0.64, 1.01]
Checkoway et al. [15] 2002 USA 210 61 347 110 0.88 [0.61, 1.28]
Total 718 2930 0.83 [0.69, 0.99]
Drinkers of >1 cups per day of tea versus non-consumers studies
Fall et al. [10] 1999 Sweden 113 7 263 31 0.49 [0.21, 1.16]
Paganini-Hill [12] 2001 USA 395 50 2320 234 1.29 [0.93, 1.79]
Checkoway et al. [15] 2002 USA 210 11 347 35 0.49 [0.24, 0.99]
Total 718 2930 0.96 [0.73, 1.27]
N: number of cases/controls, n: number of tea drinkers in cases/controls.
Study or subgroup
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
0.01 0.1 1 10 100




0.83 [0.69, 0.99] Total (95% CI)
Total events
Checkoway et al. [15]
Fall et al. [10]
Paganini-Hill [12]
Test for overall eﬀect: Z = 2.09(P = 0.04)
Heterogeneity: χ2 = 0.2, df = 2(P = 0.91), I2 = 0%
Figure 3: Pooled estimate of OR and 95% CI of PD risk for tea drinking of ≤1 cup per day. Blue diamonds indicate adjusted OR in each
study. Open diamonds are pooled OR. Horizontal line represents 95% CI. Studies are ordered by alphabetical order of the last name of ﬁrst
author.
Study or subgroup M-H, ﬁxed, 95% CI
Odds ratio Odds ratio




0.96 [0.73, 1.27] Total (95% CI)
Total events
Heterogeneity: χ2 = 9.01, df = 2( P = 0.01), I2 = 78%
Test for overall eﬀect: Z = 0.29 (P = 0.77)
0.01 0.1 1 10 100
Favours experimental Favours control
Checkoway et al. [15]
Fall et al. [10]
Paganini-Hill [12]
Figure 4: Pooled estimate of OR and 95% CI of PD risk for tea drinking of >1 cups per day. Blue diamonds indicate adjusted OR in each
study. Open diamonds are pooled OR. Horizontal line represents 95% CI. Studies are ordered by alphabetical order of the last name of ﬁrst
author.
drinking can decrease the risk of PD. This is consistent with
the results of the similar study by Quintana et al. [6] and,
thus, further conﬁrms the relation of tea consumption and
PD. The mechanisms underlying the protective eﬀects of tea
drinking against PD risk should be multiple. In recent years,
man ynaturalproductshavebeenproposedtobemultipotent
agent to combat neurodegenerative diseases [29–32]. Firstly,
through synthesizing the studies in vitro and experimental
animal model and the epidemiological studies we collected,
we can infer that the antioxidant eﬀect of tea components,
especially polyphones, should be the predominant mech-
anism of tea against PD. Tea polyphones, such as EGCG,
have been found to exhibit neuroprotective eﬀect and the
mechanismoftheneuroprotectionmayinvolvethreeaspects:
antioxidant, anti-inﬂammatory and iron-chelating activities
[29, 33, 34]. Secondly, many other biological activities of
tea components may contribute to the beneﬁcial eﬀect of






















from each study is plotted on the horizontal axis, and its standard
error is plotted on the vertical axis.
theanine can protect the brain by promoting the secretion of
dopamine [35]. Caﬀeine has been demonstrated to be an
adenosine A2A receptor antagonist that may enhance loco-
motor activity in animal models of PD and improve motor
function in patients with PD [36]. In addition, Tan et al.
proposed that ﬂavonoids in tea with their anti-inﬂammatory
eﬀects on the cardiovascular system may help ward oﬀ PD by
increasing circulation to the brain [16].
Moreover, according to the present meta-analysis, we did
not ﬁnd an apparent dose-response relationship as expected.
It may arise from the following factors: (i) black tea and
green tea diﬀer markedly in the nature of their polyphenols
[37,38],whiletherewereonlyfewstudiesreportingstratiﬁed
results according to the types of tea and (ii) the contents
of the bioactive compounds in tea may ﬂuctuate because of
diﬀerences in producing areas, materials, and manufacturing
[37, 38].
There were heterogeneity and limitations in our study.
Firstly, the population studied in the included references
was small and their location was not widespread, which
make us unable to perform analysis on race. Secondly, other
factors with possible inﬂuence on disease progression such
as anti-Parkinsonian drugs, food supplements, or alcohol
consumption were not considered. Thirdly, there were only
few studies reporting stratiﬁed results according to speciﬁc
typesoftea(blackorgreen)andthegenderofthepopulation
studied. If more data is available in future for performing
stratiﬁed analyses according to the types of tea, through
comparing the components of the speciﬁc types of tea, we
can identify the most important compounds, which will be
of signiﬁcance to the prevention and treatment of PD.
To summarize, our ﬁndings indicate that tea drinking
can protect against PD, which leads human to value the
impact of lifestyle on health. Despite the mechanisms behind
this association should be multiple, in view of the widely
accepted pathogenic role of oxidative stress in PD and
the well-documented antioxidant potential of bioactive tea
components, the antioxidant activity is expected to be an
important aspect. Further eﬀort is encouraged to fully
understand the comprehensive mechanism underlying the
beneﬁcial eﬀect of tea consumption in lowering PD risk.
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